News headlines about AMAG Pharmaceuticals (NASDAQ:AMAG) have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the specialty pharmaceutical company an impact score of 46.5237082742865 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded down 4.98% during trading on Monday, reaching $19.10. The company had a trading volume of 819,587 shares. AMAG Pharmaceuticals has a 12 month low of $16.00 and a 12 month high of $36.83. The company’s market cap is $669.36 million. The firm has a 50 day moving average price of $18.77 and a 200 day moving average price of $21.08.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The firm had revenue of $158.39 million for the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. The business’s revenue was up 24.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.45 EPS. Analysts predict that AMAG Pharmaceuticals will post $5.40 earnings per share for the current year.

A number of research firms have recently commented on AMAG. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. ValuEngine upgraded AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Monday, July 24th. Deutsche Bank AG set a $24.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, July 7th. Finally, Citigroup Inc. dropped their price objective on AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a research note on Friday, July 7th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have issued a buy rating to the company’s stock. AMAG Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $28.09.

WARNING: “AMAG Pharmaceuticals (AMAG) Earning Somewhat Positive Media Coverage, Study Finds” was published by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $98,760.00. Following the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 3.80% of the stock is owned by corporate insiders.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Insider Buying and Selling by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.